Radionetics Oncology

Executive Summary

Radionetics Oncology is a clinical-stage biotechnology company pioneering novel small molecule radiopharmaceuticals that target G protein-coupled receptors (GPCRs) for the treatment of solid tumors. Leveraging a proprietary theranostic platform, the company develops agents capable of both diagnostic imaging and targeted radiotherapy, enabling precision medicine. By focusing on GPCRs, Radionetics addresses a largely unexplored class of targets in oncology, potentially unlocking new therapeutic avenues. The company's lead program is advancing through early clinical trials, with initial data expected to demonstrate proof-of-mechanism and safety. Radionetics' approach distinguishes itself from antibody-based radiopharmaceuticals by utilizing small molecules, which offer faster clearance, deeper tumor penetration, and potentially lower off-target toxicity. The company is headquartered in San Diego and remains privately held, with significant potential for partnerships or additional financing as clinical data matures. Given the growing interest in radiopharmaceuticals and the novel GPCR-targeting strategy, Radionetics positions itself at the forefront of a transformative area in oncology.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead GPCR-targeting radiopharmaceutical60% success
• Q2 2026Series B or strategic partnership financing70% success
• Q3 2026IND submission for second pipeline candidate50% success